Cromwell Holdings LLC Has $33,000 Position in Teleflex Incorporated (NYSE:TFX)

Cromwell Holdings LLC raised its holdings in Teleflex Incorporated (NYSE:TFX) by 59.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 132 shares of the medical technology company’s stock after buying an additional 49 shares during the quarter. Cromwell Holdings LLC’s holdings in Teleflex were worth $33,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in TFX. Mirae Asset Global Investments Co. Ltd. bought a new stake in Teleflex in the first quarter valued at about $2,467,000. ProShare Advisors LLC boosted its holdings in Teleflex by 34.1% during the first quarter. ProShare Advisors LLC now owns 12,200 shares of the medical technology company’s stock valued at $2,759,000 after purchasing an additional 3,105 shares in the last quarter. Tidal Investments LLC grew its stake in shares of Teleflex by 214.7% in the 1st quarter. Tidal Investments LLC now owns 6,644 shares of the medical technology company’s stock valued at $1,503,000 after purchasing an additional 4,533 shares during the period. Boston Trust Walden Corp raised its holdings in shares of Teleflex by 2.7% in the 2nd quarter. Boston Trust Walden Corp now owns 233,913 shares of the medical technology company’s stock worth $49,199,000 after buying an additional 6,076 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Teleflex by 15.8% during the 1st quarter. Russell Investments Group Ltd. now owns 18,838 shares of the medical technology company’s stock worth $4,245,000 after buying an additional 2,570 shares during the period. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Stock Down 0.8 %

Shares of NYSE TFX opened at $233.65 on Friday. Teleflex Incorporated has a 12-month low of $177.63 and a 12-month high of $257.85. The firm’s 50-day simple moving average is $241.03 and its 200 day simple moving average is $223.68. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.36. The company has a market cap of $11.01 billion, a price-to-earnings ratio of 41.95, a price-to-earnings-growth ratio of 2.15 and a beta of 1.16.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, August 1st. The medical technology company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.33 by $0.09. The company had revenue of $749.70 million for the quarter, compared to analyst estimates of $762.98 million. Teleflex had a net margin of 8.76% and a return on equity of 14.51%. Teleflex’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business earned $3.41 earnings per share. On average, research analysts expect that Teleflex Incorporated will post 13.97 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were paid a $0.34 dividend. The ex-dividend date was Thursday, August 15th. This represents a $1.36 annualized dividend and a dividend yield of 0.58%. Teleflex’s dividend payout ratio (DPR) is currently 24.42%.

Insider Transactions at Teleflex

In related news, Director Stuart A. Randle sold 2,674 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $238.93, for a total value of $638,898.82. Following the transaction, the director now owns 5,496 shares in the company, valued at $1,313,159.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.43% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on TFX shares. Truist Financial upped their price target on Teleflex from $247.00 to $255.00 and gave the company a “hold” rating in a research report on Monday, October 14th. Stephens boosted their target price on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Royal Bank of Canada increased their target price on shares of Teleflex from $260.00 to $275.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Finally, Piper Sandler upgraded shares of Teleflex from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $205.00 to $245.00 in a research report on Monday, July 1st. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $268.86.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.